Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.
  • Posted by Rachel Howard
  • February 16, 2017
  • Videos

Women's health in emerging markets

Why can understanding and improving women’s health in emerging markets be challenging? What strategies can global pharma develop to support women and overcome these challenges? Associate Director Rachel Howard and Research Manager Helen Mace discuss why market research is useful for understanding behaviours and attitudes to different women’s health issues  in emerging markets.

read more »

  • Posted by Rachel Howard
  • February 15, 2017
  • Articles

Cool heads in a crisis?

Cool heads in a crisis?

Understanding the role pharmaceutical companies can play in fighting today’s global health pandemics

First there was Ebola and now there is Zika; two official World Health Organization (WHO) Public Health Emergencies of International Concern (PHEIC) within as many years.  Whenever global health crises such as these emerge, the pharmaceutical industry comes under intense scrutiny for not having an immediate solution available. Part of the problem is that prevention is not always financially viable; the substantial R&D costs of developing vaccines or treatments for all known and potential threats that may or may not one day develop into global pandemics is not a feasible burden for the industry to carry alone. 

read more »

  • February 8, 2017
  • News

Research Partnership has published a new Living with Living with Lupus (SLE) market report for 2017

Research Partnership has published a new Living with Living with Lupus (SLE) market report for 2017

SLE is a progressive and debilitating disease which affects 5 million people worldwide. Living with Lupus (SLE) is a quantitative study conducted online amongst patients in the US and France and Germany. The report consists of 30-minute online interviews with 262 SLE patients (including those with lupus nephritis); fifteen follow-up qualitative interviews were also conducted. All patients were required to be on an immunosuppressant or biologic therapy; the final sample includes 15-20% on biologics.

read more »

  • Posted by Conor O'Kane
  • January 23, 2017
  • Articles

Access and elimination: the future of DAAs in hepatitis C

Access and elimination: the future of DAAs in hepatitis C

Published in Pharmaphorum January 2017

The dramatic improvements in safety, efficacy, tolerability and convenience from the first wave of direct-acting antivirals (DAAs) have made a substantial contribution to changing both the treatment paradigm and the long-term prognosis for hepatitis C. 
 The arrival of interferon-free, orally administered direct-acting antivirals (DAAs) in 2014 was a leap forward for the treatment of hepatitis C (HCV), a disease responsible for some 700,000 deaths globally each year.

read more »

  • Posted by Julie Denny
  • January 23, 2017
  • Events

EphMRA One Day Meeting

EphMRA One Day Meeting

We are delighted to be attending and presenting a paper at the EphMRA one day meeting on Tuesday 21st February, in London

Emerging markets expert Rachel Howard will be presenting the paper ‘Patient Willingness to Pay in the Real World’ from 14.35 - 15.05pm. A critical part of any self-paid healthcare product’s launch strategy is to set the right price, one which patients are willing to pay.

read more »